IN2012DN02763A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02763A
IN2012DN02763A IN2763DEN2012A IN2012DN02763A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A IN 2763DEN2012 A IN2763DEN2012 A IN 2763DEN2012A IN 2012DN02763 A IN2012DN02763 A IN 2012DN02763A
Authority
IN
India
Prior art keywords
disease
kinase activity
lrrk2 kinase
larly
particu
Prior art date
Application number
Other languages
English (en)
Inventor
Bamborough Paul
John Eatherton Andrew
Louise Nichols Paula
Singh Jandu Karamjit
James Philps Oliver
Andreotti Daniele
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2012DN02763A publication Critical patent/IN2012DN02763A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2763DEN2012 2009-09-29 2010-09-27 IN2012DN02763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24655009P 2009-09-29 2009-09-29
CN2010001334 2010-09-02
PCT/CN2010/001501 WO2011038572A1 (en) 2009-09-29 2010-09-27 Novel compounds

Publications (1)

Publication Number Publication Date
IN2012DN02763A true IN2012DN02763A (zh) 2015-09-18

Family

ID=43825509

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2763DEN2012 IN2012DN02763A (zh) 2009-09-29 2010-09-27

Country Status (15)

Country Link
US (1) US8778939B2 (zh)
EP (1) EP2483254B1 (zh)
JP (1) JP5752691B2 (zh)
KR (1) KR20120081609A (zh)
AU (1) AU2010302842B2 (zh)
BR (1) BR112012006859A2 (zh)
CA (1) CA2775753A1 (zh)
EA (1) EA021437B1 (zh)
ES (1) ES2512727T3 (zh)
IL (1) IL218674A (zh)
IN (1) IN2012DN02763A (zh)
MX (1) MX2012003778A (zh)
SG (1) SG179120A1 (zh)
WO (1) WO2011038572A1 (zh)
ZA (1) ZA201201877B (zh)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2576541T (pt) 2010-06-04 2016-07-08 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
AR082827A1 (es) * 2010-09-02 2013-01-09 Glaxo Group Ltd Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson
PT2638031T (pt) 2010-11-10 2018-01-03 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2
US9604978B2 (en) 2011-05-03 2017-03-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
BR112013030095A2 (pt) 2011-05-23 2019-09-24 Elan Pharm Inc inibidores de atividade de lrrk2 cinase
BR112014007654A8 (pt) 2011-09-30 2018-06-12 Ipsen Pharma Inibidores de lrrk2 quinase macrocíclicos.
WO2013079505A1 (en) 2011-11-29 2013-06-06 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as lrrk2 modulators
US8791130B2 (en) 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
MX349556B (es) 2011-11-29 2017-08-03 Genentech Inc Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
RU2650641C2 (ru) 2011-11-30 2018-04-16 Дженентек, Инк. Фтор-18 и углерод-11 меченые радиолиганды для томографии с позитронной эмиссией (рет), визуализирующей lrrk2
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
ES2865058T3 (es) * 2013-12-09 2021-10-14 Unichem Lab Ltd Un proceso mejorado para la preparación de (3R,4R)-(1-bencil-4-metilpiperidin-3-il)-metilamina
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015113452A1 (en) * 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
CN106604913A (zh) 2014-03-31 2017-04-26 纽约哥伦比亚大学理事会 组蛋白乙酰基转移酶激活剂及其用途
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
CA2954212C (en) 2014-07-31 2023-09-19 Basf Se Process for preparing pyrazoles
CN105348182B (zh) * 2014-08-24 2018-04-13 复旦大学 2‑烷氧基苯甲酰芳胺类化合物及其药物用途
SG11201701936WA (en) 2014-09-17 2017-04-27 Oncodesign Sa Macrocyclic lrrk2 kinase inhibitors
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CA3187499A1 (en) * 2015-05-11 2016-11-17 Eric George KLAUBER Process for preparing 4-amino-pyridazines
DK3294725T3 (da) * 2015-05-11 2021-07-26 Basf Se Fremgangsmåde til fremstilling af 4-aminopyridaziner
WO2016201096A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
EP3334740A4 (en) 2015-08-12 2019-02-06 Axovant Sciences GmbH GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS
WO2017046675A1 (en) 2015-09-14 2017-03-23 Pfizer Inc. Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
JP2019522671A (ja) 2016-07-12 2019-08-15 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺虫剤としての二環式化合物
WO2018082964A1 (en) 2016-11-04 2018-05-11 Basf Se Process for the production of pyridazinyl-amides in a one-pot synthesis
EP3573956A4 (en) * 2017-01-25 2020-08-12 GlaxoSmithKline Intellectual Property Management Limited LINKS
US20210267997A1 (en) 2017-02-24 2021-09-02 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer
KR101990738B1 (ko) 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101990739B1 (ko) 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101992059B1 (ko) 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
AU2020337720B2 (en) 2019-08-30 2024-02-15 Tsd Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449691A (en) * 1991-12-31 1995-09-12 Sterling Winthrop Inc. 3,4-disubstituted anilines-immunomodulating agents
WO1997008135A1 (de) 1995-08-30 1997-03-06 Bayer Aktiengesellschaft Acylaminosalicylsäureamide und ihre verwendung als schädlingsbekämpfungsmittel
ES2387211T3 (es) 1997-05-07 2012-09-18 University Of Pittsburgh Inhibidores de proteínas isoprenil transferass
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
RU2202344C2 (ru) 1998-03-26 2003-04-20 Джапан Тобакко Инк. Антагонисты ноцицептина, производные амида, аналгетик, способ инициирования антагонистического действия к ноцицептину, способ лечения боли, фармацевтические композиции
EP1263756B1 (en) 2000-03-17 2004-02-25 Bristol-Myers Squibb Pharma Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
DE10159453A1 (de) 2001-12-04 2003-06-18 Merck Patent Gmbh Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
CA2482341A1 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel methoxybenzamide compounds for use in mch receptor related disorders
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
EP1620422A2 (en) 2003-04-30 2006-02-01 The Institutes for Pharmaceutical Discovery, LLC Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
JPWO2005073210A1 (ja) * 2004-01-28 2007-09-06 キッセイ薬品工業株式会社 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途
WO2006003923A1 (ja) 2004-06-30 2006-01-12 Sankyo Company, Limited 置換ベンゼン化合物
US7671077B2 (en) 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
US20060276496A1 (en) * 2005-03-17 2006-12-07 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-Cytokine Heterocyclic Compounds
EP1940767A2 (en) * 2005-09-07 2008-07-09 Plexxikon, Inc. Pparactive compounds
JP2007176799A (ja) 2005-12-27 2007-07-12 Sankyo Co Ltd 置換ベンゼン化合物を含有する医薬
EA200801945A1 (ru) 2006-03-07 2009-02-27 Бристол-Маерс Сквибб Компани Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
EP2019824A2 (en) 2006-04-28 2009-02-04 Transtech Pharma, Inc. Benzamide glucokinase activators
EA015931B1 (ru) * 2006-12-15 2011-12-30 Глэксо Груп Лимитед Бензамидные производные как агонисты ер-рецепторов
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
GB0722680D0 (en) 2007-11-19 2007-12-27 Topotarget As Therapeutic compounds and their use
US20110230536A1 (en) 2008-10-24 2011-09-22 Calcimedica, Inc. Phenylpyrazole inhibitors of store operated calcium release

Also Published As

Publication number Publication date
EA021437B1 (ru) 2015-06-30
BR112012006859A2 (pt) 2019-09-24
EP2483254A4 (en) 2013-02-27
US8778939B2 (en) 2014-07-15
ZA201201877B (en) 2012-11-28
MX2012003778A (es) 2012-06-01
US20120184553A1 (en) 2012-07-19
CA2775753A1 (en) 2011-04-07
WO2011038572A1 (en) 2011-04-07
EP2483254B1 (en) 2014-08-13
IL218674A (en) 2015-11-30
KR20120081609A (ko) 2012-07-19
EA201270480A1 (ru) 2013-08-30
JP5752691B2 (ja) 2015-07-22
ES2512727T3 (es) 2014-10-24
JP2013505969A (ja) 2013-02-21
SG179120A1 (en) 2012-05-30
AU2010302842B2 (en) 2014-05-08
IL218674A0 (en) 2012-05-31
EP2483254A1 (en) 2012-08-08
AU2010302842A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
IN2012DN02763A (zh)
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
MX2009000333A (es) Pirrilopirimidinas para composiciones farmaceuticas.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
BR112012006858A2 (pt) metodo de aperfeicoamento do desempenho de impressao em placas de impressao flexografica
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2009010407A (es) Derivados fluorados de deferiprona.
TNSN07383A1 (en) 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
TW200726763A (en) Novel compound
MY150931A (en) Substituted oxazolidinones and their use
MX2010009837A (es) Tiazolil-dihidro-indazoles.
TN2011000531A1 (en) 5- alkynyl - pyridines
WO2011008675A3 (en) Catecholamine compounds, compositions, and formulations, and methods of using the same
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use
MX2012008359A (es) 5-alquinil pirimidinas y su uso como inhibidores de quinasa.